Sentinel node biopsy as an adjunct to limb salvage surgery for epithelioid sarcoma of the hand

Seal, Alex; Tse, Raymond; Wehrli, Bret; Hammond, A.; Temple, Claire

doi:10.1186/1477-7819-3-41

Cited by 15 publications

(20 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As compared to other types of soft tissue sarcomas, the spread to regional lymph nodes can occur more frequently (> 20%) [ 75 , 76 , 77 , 78 ], but the most common site of metastasis is the lung and pleura [ 12 , 23 , 25 , 29 , 68 , 70 , 78 ]. This higher rate of nodal involvement may justify performing sentinel node biopsy in selected cases, but existing data show the low percentage of finding metastatic tumors in clinically noninvolved nodes [ 76 , 79 , 80 , 81 ]. In the case of the presence of lymph node metastasis, therapeutic lymph node dissection is indicated [ 23 , 67 , 78 ].…”

Section: Surgical Treatmentmentioning

confidence: 99%

Epithelioid Sarcoma—From Genetics to Clinical Practice

Czarnecka

Sobczuk

Kostrzanowski

et al. 2020

Cancers

View full text Add to dashboard Cite

Epithelioid sarcoma is a mesenchymal soft tissue sarcoma often arising in the extremities, usually in young adults with a pick of incidence at 35 years of age. Epithelioid sarcoma (ES) is characterized by the loss of SMARCB1/INI1 (integrase interactor 1) or other proteins of the SWI/SNF complex. Two distinct types, proximal and distal, with varying biology and treatment outcomes, are distinguished. ES is known for aggressive behavior, including a high recurrence rate and regional lymph node metastases. An optimal long-term management strategy is still to be defined. The best treatment of localized ES is wide surgical resection. Neo-adjuvant or adjuvant radiotherapy may be recommended, as it reduces the local recurrence rate. Sentinel lymph node biopsy should be considered in ES patients. Patients with metastatic ES have a poor prognosis with an expected median overall survival of about a year. Doxorubicin-based regimens are recommended for advanced ES. Tazemetostat, an EZH2 methyltransferase, has shown promising results in ES patients. Novel therapies, including immunotherapy, are still needed.

show abstract

Section: Surgical Treatmentmentioning

confidence: 99%

Epithelioid Sarcoma—From Genetics to Clinical Practice

Czarnecka

Sobczuk

Kostrzanowski

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…ES has a propensity for regional lymphatic spread and SLNB offers the advantage of a minimally invasive lymph-node staging procedure, which can improve the dismal prognosis and survival rates associated with this tumor. It also allows for the accurate early detection of micrometastasis, thereby sparing patients the morbidity associated with a regional lymphadenectomy [ 8 , 12 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…Adjuvant chemotherapy (ifosfamide and doxorubicin) can be used in cases of advanced metastatic ES and can also be used as neoadjuvant therapy to reduce the tumor burden (shrink the tumor) before surgery. However, the role of chemotherapy in non-metastatic disease is unclear as the responses to chemotherapy are of short duration [ 12 , 15 ]. Future studies with long-term follow-up will be needed to establish the role of chemoradiotherapy in the treatment of ES.…”

Section: Discussionmentioning

confidence: 99%

Epithelioid Sarcoma of Upper Extremity: Diagnostic Dilemma With Therapeutic Challenges

Alexander

2021

Cureus

View full text Add to dashboard Cite

Epithelioid sarcoma is a rare, slow-growing, malignant tumor with multivariate presentation and a high rate of recurrence following surgery. Diagnosis is often missed or delayed due to its infrequent nature and confusing clinical and pathological presentation. This is compounded by the fact that this tumor is aggressive with a propensity for metastases without being detected. The treatment of this deadly tumor is controversial with no clear-cut consensus. The author presents a case of epithelioid sarcoma in the finger of a young patient with subsequent recurrence after surgery and a review of current literature pertaining to this aggressive tumor. This report would like to stress the importance of a multimodal approach in combatting this tumor as prompt diagnosis and aggressive therapy can significantly reduce the poor outcomes associated with this disease.

show abstract

“…Such reconstructions include the reconstructions of tendon, muscle, and nerve function and are increasingly being employed in trauma cases, yet are not standard of care in any STS. 43,44 Nerve reconstructions provide the opportunity to not only regain motor function, but also restore lost sensation. Moberg already proposed in the '50s that an insensate hand as good is as a non-functional hand.…”

Section: Functional Statusmentioning

confidence: 99%

“…1 Pediatric MPNST Malignant peripheral nerve sheath tumors in pediatric patients have been described previously. 32,[41][42][43][44][45] 5-year overall survival in children varies between 34.6% and 51%. 32,41,42,44,45 No institutional study has yet been able to find a difference in survival between pediatric and adult tumors.…”

Section: Extremity Mpnstmentioning

confidence: 99%

Malignant Peripheral Nerve Sheath Tumors

Martin¹

View full text Add to dashboard Cite

Chapter 1General introduction and thesis outline Part I Oncological Outcomes and Treatment of MPNSTChapter 2 Treatment and survival differences across tumor sites in malignant peripheral nerve sheath tumors: a SEER database analysis and review of the literature Neuro-Oncology Practice (2019) Chapter 3 A nationwide cohort study on treatment and survival in patients with malignant peripheral nerve sheath tumors European Journal of Cancer (2020) Chapter 4 Neurofibromatosis-associated malignant peripheral nerve sheath tumors in children have a worse prognosis: a nationwide cohort study Pediatric Blood & Cancer (2020) Chapter 5 Oncological treatment considerations differ across surgical subspecialties treating malignant peripheral nerve sheath tumors: an international survey Sarcoma (2020) Chapter 6 A Bayesian approach for diagnostic accuracy of malignant peripheral nerve sheath tumors: a systematic review and meta-analysis Submitted Chapter 7 Non-cytotoxic systemic treatment in malignant peripheral nerve sheath tumors (MPNST): a systematic review from bench to bedside Critical Reviews in Oncology/Hematology (2019) Part II Functional Outcomes and Possibilities for Treatment in MPNST Chapter 8 Resuscitating extremities after soft tissue sarcoma resections: are functional reconstructions an overlooked option in limb salvage? A systematic review European Journal of Surgical Oncology (2019) Chapter 9A systematic review of functional outcomes after nerve reconstruction in extremity soft tissue sarcomas: a need for general implementation in the armamentarium

show abstract

Sentinel node biopsy as an adjunct to limb salvage surgery for epithelioid sarcoma of the hand

Abstract: The rarity of this tumor makes definitive conclusions difficult but SLN biopsy appears to be a useful adjunct in the treatment of these sarcomas.

Cited by 15 publications

References 30 publications

Epithelioid Sarcoma—From Genetics to Clinical Practice

Epithelioid Sarcoma—From Genetics to Clinical Practice

Epithelioid Sarcoma of Upper Extremity: Diagnostic Dilemma With Therapeutic Challenges

Malignant Peripheral Nerve Sheath Tumors

Contact Info

Product

Resources

About